Key Takeaways Sanofi seeks FDA approval to expand Tzield use to children aged one and older with stage 2 T1D.SNY's filing received priority review, with an FDA decision expected by April 29, 2026.The application is backed by interim phase IV PETITE-T1D data in children under eight.Sanofi (SNY) announced that the FDA has accepted a regulatory filing seeking to expand the use of its type 1 diabetes (T1D) drug, Tzield (teplizumab), in individuals aged one year and older. The agency has granted priority review ...